Long-Awaited CLIA Draft Guidance Offers Some Leeway For Study Design
This article was originally published in The Gray Sheet
Executive Summary
FDA's CLIA waiver application draft guidance could offer test sponsors added flexibility in designing clinical studies
You may also be interested in...
FDA Says Final CLIA Waiver Guidance Eases Burdens; Industry Isn’t Satisfied
Final guidelines to companies developing point-of-care diagnostic tests for use in less sophisticated laboratories offer more leeway in clinical trial design than FDA initially proposed
FDA Says Final CLIA Waiver Guidance Eases Burdens; Industry Isn’t Satisfied
Final guidelines to companies developing point-of-care diagnostic tests for use in less sophisticated laboratories offer more leeway in clinical trial design than FDA initially proposed
FDA Will Drop “Cycle” Goals, Prioritize Interactive Device Reviews
FDA is proposing to eliminate premarket review interim "cycle" goals in order to prioritize more informal, interactive reviews and final approval decision times under a plan for reauthorization of the medical device user fee program released April 16